{"id":"https://openalex.org/W2808020760","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e14100","title":"Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).","display_name":"Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2808020760","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e14100","mag":"2808020760"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.e14100","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e14100","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e14100","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050703926","display_name":"Karthick Vishwanathan","orcid":"https://orcid.org/0000-0002-6555-8131","observed_orcids":["https://orcid.org/0000-0002-6555-8131","https://orcid.org/0000-0003-4962-5979"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karthick Vishwanathan","raw_affiliation_strings":["Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA;","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["National Taiwan University Hospital, Taipei, Taiwan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Taiwan University Hospital, Taipei, Taiwan;","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108533300","display_name":"Jongseok Lee","orcid":"https://orcid.org/0000-0002-4340-9856","observed_orcids":["https://orcid.org/0000-0002-4340-9856"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2803058125","display_name":"Seoul National University Bundang Hospital","ror":"https://ror.org/00cb3km46","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388","https://openalex.org/I2803058125"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Jong-Seok Lee","raw_affiliation_strings":["Seoul National University, Bundang Hospital, Seongnam, Korea, The Republic of;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seoul National University, Bundang Hospital, Seongnam, Korea, The Republic of;","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2803058125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080991347","display_name":"Matthew Krebs","orcid":"https://orcid.org/0000-0001-7540-3064","observed_orcids":["https://orcid.org/0000-0001-7540-3064"]},"institutions":[{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Krebs","raw_affiliation_strings":["Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, United Kingdom;","institution_ids":["https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028792085","display_name":"Paul Alfred Dickinson","orcid":"https://orcid.org/0000-0001-6566-8915","observed_orcids":["https://orcid.org/0000-0001-6566-8915"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul A. Dickinson","raw_affiliation_strings":["Seda Pharmaceutical Development Services, Alderley Edge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seda Pharmaceutical Development Services, Alderley Edge, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066185060","display_name":"Khanh Bui","orcid":"https://orcid.org/0000-0003-2169-8797","observed_orcids":["https://orcid.org/0000-0003-2169-8797"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khanh Bui","raw_affiliation_strings":["Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA;","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110421529","display_name":"Doris K. Weilert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Doris Weilert","raw_affiliation_strings":["Quintiles Inc., Overland Park, Leawood, KS;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quintiles Inc., Overland Park, Leawood, KS;","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113319335","display_name":"Karen So","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Karen So","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Karen Thomas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Karen Thomas","raw_affiliation_strings":["Biostatics and Informatics, AstraZeneca, Macclesfield, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatics and Informatics, AstraZeneca, Macclesfield, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043235685","display_name":"Robert Donald Harvey","orcid":"https://orcid.org/0000-0002-4217-1313","observed_orcids":["https://orcid.org/0000-0002-4217-1313"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R Donald Harvey","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA;","institution_ids":["https://openalex.org/I4390039307"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"e14100","last_page":"e14100"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.5375999808311462,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.5375999808311462,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.45680001378059387,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/itraconazole","display_name":"itraconazole","score":0.9449999928474426},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":1.0},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8870000243186951},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9089999794960022},{"id":"https://openalex.org/keywords/cyp3a4-inhibition","display_name":"CYP3A4 inhibition","score":0.9879999756813049},{"id":"https://openalex.org/keywords/cyp3a4-induction","display_name":"CYP3A4 induction","score":0.953000009059906},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.8339999914169312},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8029999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8881617188453674},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8306632041931152},{"id":"https://openalex.org/C2777071850","wikidata":"https://www.wikidata.org/wiki/Q411229","display_name":"Itraconazole","level":3,"score":0.8113733530044556},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.7998287677764893},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6574357748031616},{"id":"https://openalex.org/C2778607973","wikidata":"https://www.wikidata.org/wiki/Q422652","display_name":"Rifampicin","level":3,"score":0.5299376249313354},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33112019300460815},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2588534653186798},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.23466071486473083},{"id":"https://openalex.org/C2781069245","wikidata":"https://www.wikidata.org/wiki/Q12204","display_name":"Tuberculosis","level":2,"score":0.19230222702026367},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.16130578517913818},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.15524384379386902},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.1221843957901001},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1112130880355835},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.09158188104629517}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.e14100","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.e14100","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e14100","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2793612529","https://openalex.org/W6962870819","https://openalex.org/W2795221800","https://openalex.org/W2889340138","https://openalex.org/W3191460019","https://openalex.org/W2550838090","https://openalex.org/W4220710578","https://openalex.org/W4387439545","https://openalex.org/W2772706907","https://openalex.org/W4410260359"],"abstract_inverted_index":{"e14100":[0],"Background:":[1],"Osimertinib":[2,305],"is":[3,32,328,336],"a":[4,114],"potent,":[5],"oral,":[6],"irreversible":[7],"EGFR-TKI":[8,14],"with":[9,13,72,81,171,290,309,314,339],"efficacy":[10],"in":[11,70],"pts":[12,71,188],"sensitizing":[15],"(EGFRm)":[16],"and":[17,26,30,38,124,126,157,183,196,218,223,249,254,271,293,326,335,347],"T790M":[18],"mutation":[19],"positive":[20],"advanced":[21],"NSCLC.":[22],"Metabolism":[23],"of":[24,59,101,104,110,117,144,151,181,185,209,235,240,261,268,276,302],"osimertinib":[25,68,118,152,161,191,210,214,241,245,291,324],"its":[27,315],"metabolites":[28],"(AZ5104":[29],"AZ7550)":[31],"mediated":[33],"by":[34,280,331],"cytochrome":[35],"P450":[36],"(CYP)3A4":[37],"CYP3A5.":[39],"We":[40],"report":[41],"drug-drug":[42],"interaction":[43],"results":[44],"(Part":[45],"A)":[46],"from":[47],"2":[48],"Phase":[49],"I":[50],"open-label,":[51],"2-part":[52],"clinical":[53],"studies":[54,321],"that":[55,75,323],"investigated":[56],"the":[57,99,107,142,228,274],"effects":[58],"strong":[60,332,340],"CYP3A4":[61,333],"inhibition":[62],"(itraconazole)":[63],"or":[64],"induction":[65,259],"(rifampicin)":[66],"on":[67,90,106,121,133,147,153,167,176],"PK":[69,109,150],"EGFRm":[73],"NSCLC":[74],"had":[76,189],"progressed":[77],"after":[78,287],"prior":[79],"treatment":[80],"EGFR-TKI.":[82],"Part":[83,96,139],"B":[84],"(ongoing)":[85],"further":[86],"evaluates":[87],"pt":[88],"safety":[89,317],"osimertinib.":[91,111],"Methods:":[92],"Study":[93,136,194,197],"12":[94,195],"(NCT02157883)":[95],"A":[97,140],"evaluated":[98,141],"effect":[100,143,231,260],"multiple":[102],"doses":[103],"itraconazole":[105,127,212],"single-dose":[108],"Pts":[112,159],"received":[113,160],"single":[115],"dose":[116],"80":[119,162],"mg":[120,130,163,174],"Days":[122,134,154,168,177],"1":[123],"10":[125],"capsules":[128],"(200":[129],"twice":[131],"daily)":[132],"6\u201318.":[135],"13":[137],"(NCT02197247)":[138],"multiple-dose":[145],"rifampicin":[146,172,243,262,269,288,303],"steady-state":[148],"(ss)":[149],"28/29,":[155],"49/50":[156],"77/78.":[158],"once":[164],"daily":[165],"(qd)":[166],"1\u201377,":[169],"co-administered":[170],"(600":[173],"qd)":[175],"29\u201349.":[178],"Results:":[179],"Thirty-six":[180],"39":[182],"40":[184],"41":[186],"treated":[187],"evaluable":[190],"data":[192],"for":[193,216,247,273],"13,":[198],"respectively.":[199,257],"The":[200,237,258],"geometric":[201],"least":[202],"squares":[203],"mean":[204],"(GLSM)":[205],"ratios":[206,239],"(90%":[207],"CIs)":[208],"+":[211,242],"/":[213,244],"alone":[215,246],"Cmax":[217],"AUC":[219],"were":[220,251],"80%":[221],"(73\u201387)":[222],"124%":[224],"(115\u2013135),":[225],"respectively;":[226],"below":[227],"predefined":[229],"no":[230],"90%":[232],"CI":[233],"limit":[234],"200%.":[236],"GLSM":[238],"Css,max":[248,292],"AUCss":[250,294],"27%":[252],"(24\u201330)":[253],"22%":[255],"(19\u201324),":[256],"was":[263,306],"seen":[264],"within":[265,299],"7":[266],"days":[267],"initiation":[270],"continued":[272],"duration":[275],"treatment,":[277],"reaching":[278],"ss":[279],"3":[281,285],"weeks.":[282],"Induction":[283],"abated":[284],"weeks":[286,301],"discontinuation,":[289],"values":[295],"similar":[296],"to":[297],"baseline":[298],"4":[300],"discontinuation.":[304],"well":[307],"tolerated":[308],"reported":[310],"adverse":[311],"events":[312],"consistent":[313],"known":[316],"profile.":[318],"Conclusions:":[319],"These":[320],"show":[322],"concentration":[325],"exposure":[327],"not":[329],"affected":[330],"inhibitors":[334],"significantly":[337],"decreased":[338],"CYP3A":[341],"inducers.":[342],"Clinical":[343],"trial":[344],"information:":[345],"NCT02157883":[346],"NCT02197247.":[348]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-06-21T00:00:00"}